Scancell Holdings plc (LON:SCLP - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 10.03 ($0.14) and traded as high as GBX 10.45 ($0.14). Scancell shares last traded at GBX 9.52 ($0.13), with a volume of 177,939 shares changing hands.
Scancell Stock Performance
The company has a market capitalization of £108.97 million, a PE ratio of -504.81 and a beta of 0.35. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The company has a 50 day moving average price of GBX 10.03 and a 200 day moving average price of GBX 9.70.
Scancell (LON:SCLP - Get Free Report) last released its earnings results on Thursday, September 11th. The company reported GBX (1.26) EPS for the quarter. Equities analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current year.
Insider Activity at Scancell
In other news, insider Martin Diggle purchased 4,400,000 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were acquired at an average cost of GBX 10 per share, with a total value of £440,000. In the last three months, insiders purchased 7,652,236 shares of company stock worth $73,474,596. Corporate insiders own 15.15% of the company's stock.
Scancell Company Profile
(
Get Free Report)
Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.
Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Scancell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scancell wasn't on the list.
While Scancell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
